期刊文献+

非霍奇金淋巴瘤与乙型肝炎病毒感染的相关性

Correlation between non-Hodgkin lymphoma and hepatitis B virus infection
原文传递
导出
摘要 目的探讨非霍奇金淋巴瘤(NHL)与乙型肝炎病毒(HBV)感染的相关性。方法选取2008年1月至2013年12月间的108例NHL患者作为观察组,同期216例其他恶性肿瘤患者(原发性肝癌除外)作为对照组。比较两组患者的HBV感染率和乙肝表面抗原(HBs Ag)阳性率,分析不同NHL患者的临床资料与HBV感染的相关性。结果观察组患者的HBV感染率为38.9%(42/108),Hbs Ag阳性率为26.9%(29/108);对照组分别为21.3%(46/216)和15.3%(33/216),组间差异均有统计学意义(P<0.05)。HBV的感染率与患者的肿瘤类型和临床分期有明显相关性(P<0.05),与患者年龄和性别无明显相关性(P>0.05)。结论 NHL与HBV感染具有一定的相关性,临床上应给予一定的重视。 Objective To explore the correlation between non-Hodgkin lymphoma (NHL) and hepatitis B virus (HBV) infection. Methods A total of 108 patients with NHL during January 2008 to De- cember 2013 were chosen as observation group, and 216 patients of other cancer (except hepatoma) were chosen as control group. HBV infection rate and positive rate of hepatitis B surface antigen (HbsAg) of two groups were compared. Clinical data of NHL and HBV infection in two groups were analysed. Results In observation group, HBV infection rate was 38.9% (42/108), positive rate of HbsAg was 26. 9% (29/108). While in control group, HBV infection rate was 21.3% (46/216), positive rate of HbsAg is 15.3% (33/216), with statistical signigicance (P 〈 0. 05 ). The type and stage of N HL had signigicant relevance with infection of HBV (P 〈 0. 05 ). The age, and gender had no signigicant relevance with infec- tion of HBV ( P 〉 0. 05 ). Conclusions NHL is relative to HBV infection, which should be given some at- tention for clinicians.
出处 《中国肿瘤临床与康复》 2015年第5期536-538,共3页 Chinese Journal of Clinical Oncology and Rehabilitation
关键词 非霍奇金淋巴瘤 乙型肝炎病毒 相关性 Non-Hodgkin lymphoma Hepatitis B virus Correlation
  • 相关文献

参考文献17

  • 1Evans LS, Hancock BW. Non-Hodgkin lymphoma [ J ]. Lancet, 2003, 362 : 139-146.
  • 2Morin RD, Mendez-Lago M, Mungall A J, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma [ J ]. Na- ture, 2011,476:298-303.
  • 3Peveling-Oberhag J, Arcaini L, Hansmann M L, et al. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management [ J ]. Journal of hepatology, 2013, 59 (1) : 169-177.
  • 4Friedberg JW,Sharman J, Sweetenham J,et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non- Hodgkin lymphoma and chronic lymphocytic leukemia [ J ] Blood, 2010, 115:2578-2585.
  • 5肖畅,苏祖兰,吴秋良,郜红艺,方建晨,夏忠军,管忠震.根据WHO新分类对493例非霍奇金淋巴瘤的临床病理分析[J].中华病理学杂志,2005,34(1):22-27. 被引量:54
  • 6李开春,易克,曾晓颖,唐曦,陈玺,王静文,施展.非霍奇金淋巴瘤预后因素的初步分析[J].中华肿瘤防治杂志,2010,17(17):1371-1373. 被引量:12
  • 7Raj V S, Mou H, Smits S L, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC [J]. Nature, 2013, 495(7440) : 251-254.
  • 8谢智勇,马新玥,万莉,马磊,张琦,杨映,颜其贵.羊地方性鼻内肿瘤病毒SU基因的克隆与原核表达[J].中国兽医科学,2013,43(11):1175-1179. 被引量:5
  • 9吴克复,马小彤,郑国光,宋玉华.病毒的致癌作用和治癌作用[J].白血病.淋巴瘤,2012,21(6):321-324. 被引量:11
  • 10Lemon SM, McGivern DR. Is hepatitis C virus carcinogenic'? [ J]. Gastroenterology, 2012, 142:1274-1278.

二级参考文献40

  • 1刘华,王蔚,陈俊民,郑垂志.乙型肝炎病毒感染与恶性淋巴瘤关系的探讨[J].白血病.淋巴瘤,2005,14(1):27-28. 被引量:21
  • 2罗耀星,张吉凯,李建基,李辉,蔡汉港,方苓,陆碧如,阳文胜.广东省2002年病毒性肝炎血清流行病学调查分析[J].中国计划免疫,2005,11(2):89-92. 被引量:51
  • 3Miehallet A S, Coiffier B. Recent developments in the treatment of aggressive non ttodgkin lymphoma[J]. Blood Rev, 2009, 23(1):11 -23.
  • 4Chihara D, Oki Y,Ine S, et al. Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy[J]. Leuk Lymphoma. 2009, 50(12) : 1999-2004.
  • 5Armitage J O. Staging non Hodgkinlvmphoma[J] . CA Cancer J Clin,2005.55:368 -376.
  • 6Mawardi H, Cutler C, Treister N. Medical management update: Non- Hodgkin lymphoma[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2009, 107 ( 1 ) : 19- 33.
  • 7Prichard M, Harris T, Williams M E, et al. Treatment strategies for relapsed and refractory aggressive non Hodgkin's lymphoma[J]. Expert Opin Pharmacother, 2009, 10(6) : 982- 995.
  • 8Paydas S, Ergin M, Seydaoglu G, et al. Prognostic significance of angiogenic lymphangiogenic, anti apoptotic, inflarmatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature[J].Leuk Res, 2009,33(12): 1627 -1635.
  • 9Tzankov A, Zlobee I, Went P, et al. Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut- off scores[J ]. Leuk Lymphoma, 2010. 51(2): 199 -212.
  • 10彭文伟.传染病学[M](第6版)[M].北京:人民卫生出版社,2003.85.

共引文献111

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部